Long-term follow-up of chemonaive patients with asymptomatic metastatic colorectal cancer treated with enzastaurin in a window of opportunity phase II study

Annals of Oncology

Volumn 21, Issue 5, 2009, Pages 1127-1128

  Glimelius, B ^a,b   Spindler, K L ^c   Frodin J E ^b   Berglund, A ^a,b   Qvortrup, C ^d   Jakobsen, A ^c   Pfeiffer, P ^d  

^a UPPSALA UNIVERSITY   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c LILLEBAELT HOSPITAL   (Denmark)

^d ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ENZASTAURIN;

CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; DRUG EFFICACY; DRUG RESPONSE; FOLLOW UP; HUMAN; KAPLAN MEIER METHOD; LETTER; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SURVIVAL TIME; UNSPECIFIED SIDE EFFECT;

EID: 77951218478     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp526     Document Type: Letter

References (4)

1. Glimelius B, Lahn M, Gawande S et al. A window of opportunity phase II study of enzastaurin in chemonaive patients with asymptomatic metastatic colorectal cancer. Ann Oncol 2010; 21: 1020-1026.
2. Graff JR, McNulty AM, Hanna KR et al. The protein kinase Cbeta-selective inhibitor, enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res 2005; 65: 7462-7469.
3. Fleming TR, Rothmann MD, Lu HL. Issues in using progression-free survival when evaluating oncology products. J Clin Oncol 2009; 27: 2874-2880.
4. Golfinopoulos V, Salanti G, Pavlidis N, Ioannidis JP. Survival and disease-progression benefits with treatment regimens for advanced colorectal cancer: a meta-analysis. Lancet Oncol 2007; 8: 898-911.